Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14668523 | 0.97 | DNM1 (0.52) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL16090593 | 0.92 | MEN1 (0.42) | DNM1FAAHMEN1KMT2ACA1 | |
| SCHEMBL12967466 | 0.82 | DNM1 (0.46) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL9320204 | 0.82 | DNM1 (0.52) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL2715609 | 0.80 | CA1 (0.48) | CA1 | |
| SCHEMBL23375455 | 0.80 | CHRM2 (0.37) | DNM1MEN1KMT2ACA1TSHR | |
| SCHEMBL291780 | 0.80 | DNM1 (0.44) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL12967471 | 0.80 | DNM1 (0.50) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL5253528 | 0.80 | DNM1 (0.50) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL12967474 | 0.80 | DNM1 (0.50) | DNM1S1PR2S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119508-A1 | Multi-Route Administration Of Immune Response Modifier Compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119508-A1 | Multi-Route Administration Of Immune Response Modifier Compounds | IFNG, HLA-DRB1, IL2 | DNM1 3571/4885S1PR2 1165/4885S1PR1 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.